Kate Smolina1, Laura Ball2, Karin H Humphries2, Nadia Khan2, Steven G Morgan2. 1. From the Centre for Health Services and Policy Research, School of Population and Public Health (K.S., L.B., S.G.M.), Division of Cardiology (K.H.H.), and Division of General Internal Medicine (N.K.), University of British Columbia, Vancouver, British Columbia, Canada. kate.smolina@ubc.ca. 2. From the Centre for Health Services and Policy Research, School of Population and Public Health (K.S., L.B., S.G.M.), Division of Cardiology (K.H.H.), and Division of General Internal Medicine (N.K.), University of British Columbia, Vancouver, British Columbia, Canada.
Abstract
BACKGROUND: The prevalence of the use of secondary prevention cardiovascular medications is lower among women than men, but it is unclear if this is a result of lower treatment initiation among women or lower treatment adherence. We aimed to map the treatment pathway for survivors of acute myocardial infarction (AMI) by sex and age. METHODS AND RESULTS: This retrospective population-based cohort study used linked administrative data sets in British Columbia (2004-2011), which include health care, prescription drugs, sociodemographic, and mortality information. The study cohort included all individuals admitted to hospital for AMI in 2007-2009 and survived for 1 year after hospital discharge. Patients were evaluated for whether they initiated and then subsequently filled prescriptions angiotensin-converting enzyme inhibitors, β-blockers, and statins. More than two thirds of AMI survivors initiated treatment on all appropriate medications, given their contraindications, within 2 months of discharge. Younger men were significantly more likely than younger women to initiate appropriate treatment (adjusted odds ratio, 1.38; 95% confidence interval, 1.10-1.75). By the end of 1 year after discharge, only one third of all AMI survivors filled all appropriate prescriptions for at least 80% of the year. There was no significant difference in adherence to medication therapy between women and men. CONCLUSIONS: The majority of AMI survivors either discontinue treatment or do not refill their prescriptions consistently. Women <55 years are significantly less likely to be on optimal therapy by the end of 1 year after discharge, which is driven by a sex disparity in treatment initiation and not treatment adherence.
BACKGROUND: The prevalence of the use of secondary prevention cardiovascular medications is lower among women than men, but it is unclear if this is a result of lower treatment initiation among women or lower treatment adherence. We aimed to map the treatment pathway for survivors of acute myocardial infarction (AMI) by sex and age. METHODS AND RESULTS: This retrospective population-based cohort study used linked administrative data sets in British Columbia (2004-2011), which include health care, prescription drugs, sociodemographic, and mortality information. The study cohort included all individuals admitted to hospital for AMI in 2007-2009 and survived for 1 year after hospital discharge. Patients were evaluated for whether they initiated and then subsequently filled prescriptions angiotensin-converting enzyme inhibitors, β-blockers, and statins. More than two thirds of AMI survivors initiated treatment on all appropriate medications, given their contraindications, within 2 months of discharge. Younger men were significantly more likely than younger women to initiate appropriate treatment (adjusted odds ratio, 1.38; 95% confidence interval, 1.10-1.75). By the end of 1 year after discharge, only one third of all AMI survivors filled all appropriate prescriptions for at least 80% of the year. There was no significant difference in adherence to medication therapy between women and men. CONCLUSIONS: The majority of AMI survivors either discontinue treatment or do not refill their prescriptions consistently. Women <55 years are significantly less likely to be on optimal therapy by the end of 1 year after discharge, which is driven by a sex disparity in treatment initiation and not treatment adherence.
Authors: Kelly C Epps; Elizabeth M Holper; Faith Selzer; Helen A Vlachos; Sarah K Gualano; J Dawn Abbott; Alice K Jacobs; Oscar C Marroquin; Srihari S Naidu; Peter W Groeneveld; Robert L Wilensky Journal: Circ Cardiovasc Qual Outcomes Date: 2016-02
Authors: Yuan Lu; Shengfan Zhou; Rachel P Dreyer; Michael Caulfield; Erica S Spatz; Mary Geda; Nancy P Lorenze; Peter Herbert; Gail D'Onofrio; Elizabeth A Jackson; Judith H Lichtman; Héctor Bueno; John A Spertus; Harlan M Krumholz Journal: Am Heart J Date: 2016-10-03 Impact factor: 4.749
Authors: Jacob A Udell; Gregg C Fonarow; Thomas M Maddox; Christopher P Cannon; W Frank Peacock; Warren K Laskey; Maria V Grau-Sepulveda; Eric E Smith; Adrian F Hernandez; Eric D Peterson; Deepak L Bhatt Journal: Clin Cardiol Date: 2018-05-11 Impact factor: 2.882
Authors: Rachel P Dreyer; Christopher Sciria; Erica S Spatz; Basmah Safdar; Gail D'Onofrio; Harlan M Krumholz Journal: Circ Cardiovasc Qual Outcomes Date: 2017-02-22
Authors: D C Eindhoven; L N van Staveren; J A van Erkelens; D E Ikkersheim; S C Cannegieter; V A W M Umans; A Mosterd; J van Wijngaarden; M J Schalij; C J W Borleffs Journal: Neth Heart J Date: 2018-01 Impact factor: 2.380